更年期ほてり治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療タイプ別、流通チャネル別、地域別、競合別、2020年～2030年

更年期ほてり治療の世界市場規模は2024年に64億5,000万米ドルとなり、予測期間中のCAGRは5.43%で2030年には87億9,000万米ドルに達すると予測されています。

世界の更年期ほてり治療市場は、女性の健康問題に対する意識の高まりと、更年期の効果的な症状管理に対する需要の増加により、急速に発展しています。ほてりによる不快感や混乱からの解放を求める女性が増えるにつれ、市場では多様な治療オプションの導入が見られるようになっています。これには、ホルモン補充療法、非ホルモン医薬品、ハーブ療法、栄養補助食品やウェルネス・プログラムといったライフスタイル志向のソリューションなどが含まれます。

製薬会社は、効果的で副作用の少ない治療法を開発するため、研究開発に継続的に投資しています。例えば、2023年12月にJournal of the Menopause Societyに掲載された論文では、ブラジル、カナダ、メキシコ、北欧諸国などの閉経後女性1万2,268人を対象としたオンライン研究の結果が報告されています。それによると、約15.6％が中等度から重度の血管運動症状（VMS）を経験していることが明らかになりました。このような広範な有病率は、今後数年間の市場成長を促進すると予想されます。ホルモンベースの治療は、その有効性が証明されているため、依然として広く使用されているが、長期的な安全性に関する懸念から、非ホルモン代替薬への関心が高まっています。これらの代替療法は、ホルモン療法を受けられない、あるいは受けたくない女性にとって特に魅力的であり、選択的セロトニン再取り込み阻害薬、植物由来の治療法、ウェアラブル冷却技術などの技術革新に拍車をかけています。従来の治療手段に加え、個別化治療やホリスティック・ウェルネス・アプローチへのシフトも顕著です。ヘルスケアプロバイダーは、身体的症状だけでなく更年期障害の感情的・心理的側面も考慮した統合治療計画を採用するようになってきています。遠隔医療プラットフォームやデジタルヘルスツールもまた、患者エンゲージメントに大きな役割を果たしており、より良い管理とフォローアップケアを可能にしています。

市場はまた、高齢化する女性の人口増加や、多くの地域における更年期障害の非人格化など、人口統計学的・社会的変化によっても形成されています。このような文化的変化によって、より多くの女性が専門医の助けを求め、質の高い治療を求めるようになっています。その結果、市場は継続的に成長する態勢を整えており、世界中の更年期女性の多様で変化するニーズに対応する革新的な治療法を提供する既存企業および新規参入企業の双方に成長機会が生まれています。

主な市場促進要因

更年期関連の健康問題に対する意識の高まり

主な市場課題

ホルモン療法に関する安全性への懸念

主要市場動向

非ホルモン療法への嗜好の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の更年期ほてり治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（経口液剤と錠剤）
  • 治療タイプ別（ホルモン治療、非ホルモン治療、代替治療）
  • ホルモン治療（エストロゲン、エストロゲン・プロゲステロン併用、プロゲステロン）
  • 非ホルモン治療（クロニジン、ガバペンチン、プレガバリン、ブリズデル、抗うつ薬）
  • 代替治療（ビタミンE、漢方薬、ブラックコホシュ）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024年）
• 製品マップ

第6章 北米の更年期ほてり治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • ホルモン治療
  • 非ホルモン治療
  • 代替治療
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の更年期ほてり治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • ホルモン治療
  • 非ホルモン治療
  • 代替治療
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の更年期ほてり治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • ホルモン治療
  • 非ホルモン治療
  • 代替治療
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の更年期ほてり治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • ホルモン治療
  • 非ホルモン治療
  • 代替治療
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの更年期ほてり治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • ホルモン治療
  • 非ホルモン治療
  • 代替治療
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の更年期ほてり治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

第15章 1 Abbvie, Inc.

第15章 2 Allergan PLC.

第15章 3 Bayer Ag.

第15章 4 Cipla, Inc.

第15章 5 Eli Lilly and CompaBy.

第15章 6 Emcure Pharmaceuticals Ltd.

第15章 7 GSK PLC.

第15章 8 Glenmark Pharmaceuticals Ltd.

第15章 9 Hisamitsu Pharmaceutical Co. Inc.

第15章 10 Merck & Co. Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Menopausal Hot Flashes Treatment Market was valued at USD 6.45 billion in 2024 and is expected to reach USD 8.79 billion by 2030 with a CAGR of 5.43% during the forecast period. The global menopausal hot flashes treatment market is evolving rapidly, driven by growing awareness of women's health issues and increasing demand for effective symptom management during menopause. As more women seek relief from the discomfort and disruption caused by hot flashes, the market is witnessing the introduction of a diverse range of treatment options. These include hormone replacement therapies, non-hormonal pharmaceuticals, herbal remedies, and lifestyle-oriented solutions such as dietary supplements and wellness programs.

Pharmaceutical companies are continuously investing in research and development to formulate therapies that are both effective and carry fewer side effects. For example, a December 2023 article in the Journal of the Menopause Society reported findings from an online study involving 12,268 postmenopausal women across countries like Brazil, Canada, Mexico, and several Nordic nations. It revealed that around 15.6% experienced moderate to severe vasomotor symptoms (VMS). This widespread prevalence is anticipated to fuel market growth in the coming years. Hormone-based treatments remain widely used due to their proven efficacy, but concerns around long-term safety have led to a rising interest in non-hormonal alternatives. These alternatives are particularly appealing to women who are unable or unwilling to undergo hormone therapy, fueling innovation in selective serotonin reuptake inhibitors, plant-based treatments, and wearable cooling technologies. In addition to traditional treatment avenues, there is a notable shift toward personalized care and holistic wellness approaches. Healthcare providers are increasingly adopting integrated treatment plans that consider not only physical symptoms but also the emotional and psychological aspects of menopause. Telemedicine platforms and digital health tools are also playing a growing role in patient engagement, enabling better management and follow-up care.

The market is also being shaped by demographic and social changes, such as the growing population of aging women and the destigmatization of menopause in many regions. This cultural shift is empowering more women to seek professional medical help and demand high-quality treatments. As a result, the market is poised for continued growth, with opportunities emerging for both established players and new entrants offering innovative therapies that cater to the diverse and changing needs of menopausal women across the globe.

Key Market Drivers

Rising Awareness of Menopause-Related Health Issues

Rising awareness of menopause-related health issues has become a pivotal force driving the global menopausal hot flashes treatment market. For many years, menopause was considered a private or even taboo topic, leading to limited discussion and a lack of proactive medical engagement. However, in recent years, societal attitudes have shifted significantly. Health organizations, advocacy groups, and media platforms are increasingly highlighting the challenges women face during menopause, especially the disruptive symptoms such as hot flashes, night sweats, and sleep disturbances. This growing visibility has empowered women to seek medical advice and explore available treatment options more confidently. For example, in May 2023, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral treatment for moderate to severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The introduction of such innovative therapies is likely to enhance access to menopausal treatments and support market growth in the coming years.

Educational initiatives and awareness campaigns are playing a critical role in informing women about the physiological changes associated with menopause and the importance of timely intervention. These efforts are not only helping women recognize symptoms earlier but also encouraging open dialogue with healthcare providers. As a result, there is a notable increase in consultations related to menopause management, leading to greater demand for both pharmaceutical and non-pharmaceutical solutions.

Healthcare professionals are also becoming more proactive in addressing menopausal symptoms during routine check-ups, further normalizing the conversation around menopause. At the same time, the digital era has enabled access to a vast pool of information, forums, and telemedicine services, making it easier for women to educate themselves and connect with specialists from the comfort of their homes.

The increased focus on women's health across global health agendas is also pushing policymakers and healthcare providers to prioritize menopause management. This has led to the development of specialized clinics, wellness programs, and tailored treatment regimens, all aimed at improving quality of life during this transition. In turn, this heightened awareness is translating into a larger, more engaged consumer base actively seeking effective solutions for hot flashes, thereby propelling the growth of the menopausal hot flashes treatment market.

Key Market Challenges

Safety Concerns Around Hormone Therapy

Safety concerns around hormone therapy remain one of the most significant challenges in the global menopausal hot flashes treatment market. While Hormone Replacement Therapy (HRT) has long been considered the most effective option for alleviating hot flashes and other vasomotor symptoms associated with menopause, its potential risks have created a climate of caution among both patients and healthcare providers. Studies linking long-term hormone use-particularly estrogen-progestin combinations-to increased risks of breast cancer, blood clots, stroke, and cardiovascular events have led to heightened scrutiny of HRT prescriptions.

These safety concerns have prompted regulatory authorities to issue strict guidelines on the use of hormone therapy, recommending the lowest effective dose for the shortest possible duration. As a result, many women and clinicians are either reluctant to initiate or continue HRT, particularly in cases where the patient has a personal or family history of hormone-sensitive conditions. This has limited the therapy's appeal, despite its proven efficacy, and has created a significant demand for safer, non-hormonal alternatives. Moreover, the fear surrounding hormone therapy has contributed to misinformation and confusion, causing some women to avoid treatment altogether even when they might benefit from it. This underscores the need for clearer patient education and better risk-benefit communication by healthcare professionals.

These ongoing safety concerns are reshaping the treatment landscape, pushing pharmaceutical companies to innovate and develop non-hormonal therapies with better safety profiles. Addressing these concerns effectively is crucial for expanding patient access and building trust in the evolving options available for managing menopausal hot flashes.

Key Market Trends

Growing Preference for Non-Hormonal Therapies

The growing preference for non-hormonal therapies is emerging as a defining trend in the global menopausal hot flashes treatment market. Historically, hormone replacement therapy (HRT) has been the most widely used and effective option for managing vasomotor symptoms like hot flashes. However, concerns surrounding the long-term safety of HRT-including increased risks of breast cancer, stroke, and cardiovascular conditions-have led many women to seek alternative treatments. This shift in preference has opened the door for the development and adoption of non-hormonal therapies that offer relief without the potential complications associated with hormones.

Non-hormonal treatments encompass a wide range of options, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine. These medications, often prescribed off-label, have shown effectiveness in reducing hot flashes and night sweats. More recently, advancements in drug development have introduced targeted non-hormonal therapies such as neurokinin-3 (NK3) receptor antagonists, which directly act on brain pathways that regulate temperature, offering a novel mechanism of action for symptom relief. In addition to pharmaceuticals, there is increasing consumer interest in herbal supplements and plant-based remedies, such as black cohosh, soy isoflavones, and red clover. These options appeal to women looking for natural or integrative approaches, further broadening the spectrum of non-hormonal interventions. This trend is particularly important for women who are not eligible for HRT due to medical contraindications or personal choice. As healthcare providers become more aware of and confident in these alternatives, and as patients demand safer and more personalized options, the market for non-hormonal therapies is expected to expand significantly. The growing preference for such treatments underscores a broader movement toward risk-averse, patient-centric care and is reshaping the direction of innovation in the menopausal hot flashes treatment landscape.

Key Market Players

• Abbvie, Inc.
• Allergan PLC.
• Bayer Ag.
• Cipla, Inc.
• Eli Lilly and Company.
• Emcure Pharmaceuticals Ltd.
• GSK PLC.
• Glenmark Pharmaceuticals Ltd.
• Hisamitsu Pharmaceutical Co. Inc.
• Merck & Co. Inc.

Report Scope:

In this report, the Global Menopausal Hot Flashes Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Menopausal Hot Flashes Treatment Market, By Type:

• Oral
• Liquid
• Pill

Menopausal Hot Flashes Treatment Market, By Treatment Type:

• Hormonal Treatment
• Non-Hormonal Treatment
• Alternative Treatment

Menopausal Hot Flashes Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Menopausal Hot Flashes Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.

Available Customizations:

Global Menopausal Hot Flashes Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Menopausal Hot Flashes Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Oral Liquid v/s Pill)
  • 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By CompaBy (2024)
• 5.3. Product Map

6. North America Menopausal Hot Flashes Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Oral Liquid v/s Pill)
  • 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Menopausal Hot Flashes Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Oral Liquid v/s Pill)
  • 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. GermaBy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Oral Liquid v/s Pill)
  • 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Distribution Channel

9. South America Menopausal Hot Flashes Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Oral Liquid v/s Pill)
  • 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Oral Liquid v/s Pill)
  • 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

15.1 Abbvie, Inc.

15.2 Allergan PLC.

15.3 Bayer Ag.

15.4 Cipla, Inc.

15.5 Eli Lilly and CompaBy.

15.6 Emcure Pharmaceuticals Ltd.

15.7 GSK PLC.

15.8 Glenmark Pharmaceuticals Ltd.

15.9 Hisamitsu Pharmaceutical Co. Inc.

15.10 Merck & Co. Inc.

16. Strategic Recommendations

17. About Us & Disclaimer